Antipsychotic Polypharmacy in Czech Republic and in Ukraine

  • Viktor P. Samokhvalov
  • Oksana E. Samokhvalova
  • Viktoria A. Verbenko
  • Georgij N. Verbenko
Chapter

Abstract

In prescription surveys, use of antipsychotic polypharmacy is common, despite scant supporting evidence. This study investigated the use of monotherapy and different types of polypharmacotherapy among inpatients with acute episodes of schizophrenia in the Czech Republic and in the Ukraine. Two hundred participants were enrolled from two sites: Lnare Psychiatric Clinic, Czech Republic (n = 100) and Psychiatric Hospital №1 in Simferopol, Crimea, Ukraine (n = 100). Each inpatient was evaluated twice with the Positive and Negative Symptom Scale (PANSS) at admission (acute stage) and at discharge (a stabilization stage) from hospital. This study revealed that antipsychotic polypharmacy was prescribed considerably more frequently in the Czech sample (43%) than in the Ukrainian group (29%). The use of combinations of first generation antipsychotics (FGAs) and second generation antipsychotics (SGAs) during hospitalization was six times more prevalent in the Czech Republic (31%) than in the Ukraine (5%; p < 0.001); 24% of the Ukranian inpatients received a combination of two or more FGAs, in comparison to 12% of the Czech inpatients (p < 0.05) at admission, and the rates decreased to 4% and 9%, respectively, at discharge (p < 0.05). Augmentation with off-label prescribed antidepressants and mood stabilizers was far more prevalent in the Ukraine (65 and 54%, at admission and discharge, respectively) than in the Czech sample (40 and 29%, at admission and discharge, respectively). Antipsychotic monotherapy for acute psychosis in the Czech Republic (20%; mainly SGAs) was almost three times more common than in the Ukraine (8%; mainly FGAs; t = 4.63, p < 0.001);. When the mental health condition stabilized, antipsychotic monotherapy was increased: from 20 to 33% in the Czech Republic and from 8 to 18% in the Ukraine. International multicenter studies are warranted to investigate the reasons for and the impact of the predominant use of polypharmacy.

Keywords

Czech Republic Mood Stabilizer Antipsychotic Agent Acute Psychosis Generation Antipsychotic 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Abbreviations

FGA

First generation antipsychotics

NASMHPD

National Association of State Mental Health Program Directors report

PANSS

Positive and Negative Symptom Scale of Schizophrenia

SD

Standard deviation

SGA

Second generation antipsychotics

SSRI

Selective serotonin reuptake inhibitor

Notes

Acknowledgements

The authors express their gratitude to Dr. Vladimir Muchl, the director of the psychiatric hospital in Lnare (Czech Republic), and Dr. Irina A. Strojevskaja, chief of the acute department of Crimean Psychiatric Hospital № 1(Simferopol, Crimea, Ukraine).

Authors wish to express gratitude to Ms. Rena Kurs, B.A. (Shaar-Menashe Mental Health Center, Hadera, Israel) for editorial assistance.

References

  1. 1.
    Sheppard C, Collins L, Fiorentino D et al (1969) Polypharmacy in psychiatric treatment. Incidence at a state hospital. Curr Therapy Res 11:765–774Google Scholar
  2. 2.
    Praško J, Herman E, Seiferova D (2007) Konziliární psychiatrie. Medical Tribune, PrahaGoogle Scholar
  3. 3.
    Kolvach Z, Holmerova I (2010) Geriatrická farmakoterapie. In: Marek J (ed) Farmakoterapie vnitřních nemocí. Grada Publication, Praha, pp 687–695Google Scholar
  4. 4.
    Hovstadius B, Hovstadius K, Åstrand B et al (2010) Increasing polypharmacy – an individual-based study of the Swedish population 2005–2008. BMC Clin Pharmacol 10:16PubMedCrossRefGoogle Scholar
  5. 5.
    Langan J, Shajahan P (2010) Antipsychotic polypharmacy: review of mechanisms, mortality and management. Psychiatrist 34:58–62CrossRefGoogle Scholar
  6. 6.
    Waddington JL, Youssef HA, Kinsella A (1998) Mortality in schizophrenia. Antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study. Br J Psychiatry 173:325–329PubMedCrossRefGoogle Scholar
  7. 7.
    Boschert S (2008) Practical psychopharmacology: polypharmacy in schizophrenia is often expensive, ineffective. Elsevier Global Medical News, 12 DecGoogle Scholar
  8. 8.
    Medical Directors Council (2001) Medical directors technical report on psychiatric polypharmacy. National Association of State Mental Health Programs Directors(NASMHPD) Alexandria, Virginia, 9 OctGoogle Scholar
  9. 9.
    Janssen B, Weinmann S, Berger M et al (2004) Validation of polypharmacy process measures in inpatient schizophrenia care. Schizophr Bull 30(4):1023–1033PubMedCrossRefGoogle Scholar
  10. 10.
    Tapp A, Wood AE, Secrest L et al (2003) Combination antipsychotic therapy in clinical practice. Psychiatr Serv 54(1):55–59PubMedCrossRefGoogle Scholar
  11. 11.
    Zink M, Englisch S, Meyer-Lindenberg A (2010) Polypharmacy in schizophrenia. Curr Opin Psychiatry 23(2):103–111PubMedCrossRefGoogle Scholar
  12. 12.
    Kreyenbuhl J, Marcus SC, West JC et al (2007) Adding or switching antipsychotic medication in treatment-refractory schizophrenia. Psychiatr Serv 58:983–990PubMedCrossRefGoogle Scholar
  13. 13.
    Buchman RW, Kreyenbuhl J, Kelly DL et al (2010) The 2009 schizophrenia PORT psychopharmacological treatment recommendation and summary statements. Schizophr Bull 36(1):71–93CrossRefGoogle Scholar
  14. 14.
    Schizophrenia: Core Interventions in the Treatment and Management of Schizophrenia in Adults in Primary and Secondary Care (2010) National collaborating centre for mental health, national clinical guideline number 82. The British Psychological Society/The Royal College of Psychiatrists, LondonGoogle Scholar
  15. 15.
    Kapiani B (2007) The results of antipsychotic therapy of schizophrenia with connection correlated factors. Ph.D. dissertation Sankt- PetersburgGoogle Scholar
  16. 16.
    Centorrino F, Goren JL, Hennen J et al (2004) Multiple versus single antipsychotic agents for hospitalized psychiatric patients: case-control study of risks versus benefits. Am J Psychiatry 161:700–706PubMedCrossRefGoogle Scholar
  17. 17.
    Tiganov AS (1999) Schizophrenia. In: Tiganov AS (ed) Textbook of psychiatry, vol II. Medicine, Moscow, pp 407–555Google Scholar
  18. 18.
    Maljarov SA, Demchenko VA, Vitebskaja TB (2004) What should guide the physician in appointing of combination antipsychotic therapy? Health of Ukraine 96. http://www.health-ua.org/archives/health/738.html
  19. 19.
    Mosolov SN (2010) Actual theoretical problems of diagnostic, classification, neurobiology and therapy of schizophrenia: a comparison of International and Russian experience. Zh Nevrol Psikhiatr Im S S Korsakova 110(6):4–11PubMedGoogle Scholar
  20. 20.
    Freudenreich O, Goff DC (2002) Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations. Acta Psychiatrica Scand 106(5):323–330CrossRefGoogle Scholar
  21. 21.
    Christoph U, Correll CU, Rummel-Kluge C et al (2009) Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. Schizophr Bull 35(2):443–457CrossRefGoogle Scholar
  22. 22.
    Metzer HY, Kostakoglu E (2000) Combining antipsychotics: is there evidence for efficacy? Psychiatric Times 17(9):25–34Google Scholar
  23. 23.
    Stahl SM (2010) Enhancing outcomes from major depression: using antidepressant combination therapies with multifunctional pharmacologic mechanisms from the initiation of treatment. CNS Spectr 15(20):79–94PubMedGoogle Scholar
  24. 24.
    Silver H (2004) Selective serotonin re-uptake inhibitor augmentation in the treatment of negative symptoms of schizophrenia. Expert Opin Pharmacother 5(10):2053–2058PubMedCrossRefGoogle Scholar
  25. 25.
    Silver H, Chertkow Y, Weinreb O et al (2009) Multifunctional pharmacotherapy: what can we learn from study of selective serotonin reuptake inhibitor augmentation of antipsychotics in negative-symptom schizophrenia? Neurotherapeutics 6(1):86–93PubMedCrossRefGoogle Scholar
  26. 26.
    Silver H, Susser E, Danovich L et al (2011) SSRI augmentation of antipsychotic alters expression of GABA(A) receptor and related genes in PMC of schizophrenia patients. Int J Neuropsychopharmacol 14(5):573–584PubMedCrossRefGoogle Scholar
  27. 27.
    Stahl SM (2009) Stahl’s essential psychopharmacology. Neuroscientific basis and practical application, 3rd edn. Cambridge University Press, New YorkGoogle Scholar
  28. 28.
    Muijen M, Silverstone T (1987) A comparative hospital survey of psychotropic drug prescribing. Br J Psychiatry 150:501–504PubMedCrossRefGoogle Scholar
  29. 29.
    Goren JL, Parks JJ, Chinassi FA et al (2008) When is antipsychotic polypharmacy supported by research evidence & implication for QI. Jt Comm J Qual Patient Saf 34(10):571–582PubMedGoogle Scholar
  30. 30.
    Sadock BJ, Sadock VA, Ruiz P (eds) (2009) Kaplan and Sadock’s comprehensive textbook of psychiatry, vol II, 9th edn. Lippincott Williams & Wilkins, PhiladelphiaGoogle Scholar
  31. 31.
    Ghaemi SA (2002) Conceptual and historical background of polypharmacy in psychiatry. In: Ghaemi SA (ed) Polypharmacy in psychiatry. Marcel Dekker Inc, New York, pp 1–34CrossRefGoogle Scholar
  32. 32.
    Ghaemi SA (2003) Concepts of psychiatry. A plyralistic approach to mind and mental illness. The John Hopkins Press, BaltimoreGoogle Scholar
  33. 33.
    Ito C, Kubota Y, Sato MA (1999) A prospective survey on drug choice for prescriptions for admitted patients with schizophrenia. Psychiatry Clin Neurosci 53:35–40CrossRefGoogle Scholar
  34. 34.
    Tognoni G (1999) Pharmacoepidemiology of psychotropic drugs in patients with severe mental disorders in Italy. Italian Collaborative Study Group on the outcome of severe mental disorders. Eur J Clin Pharmacol 55(9):685–690PubMedCrossRefGoogle Scholar
  35. 35.
    Barnes TR, Paton C (2011) Antipsychotic polypharmacy in schizophrenia: benefits and risks. CNS Drugs 25(5):383–399PubMedCrossRefGoogle Scholar
  36. 36.
    Adeponle AB, Obembe AO, Adeyemi SO (2007) Suleiman polypharmacy in psychiatric outpatient practice in northern Nigeria. Afr J Psychiatry 10:215–218Google Scholar
  37. 37.
    Keks NA, Alston K, Hope J et al (1999) Use of antipsychosis and adjunctive medications by an inner urban community psychiatric service. Aust N Z J Psychiatry 33:896–901PubMedCrossRefGoogle Scholar
  38. 38.
    Cascade EF, Amir HK, Buckley PF (2008) Current management of schizophrenia: antipsychotic monotherapy versus combination therapy. Psychiatry (Edgemont) 5(5):28–30Google Scholar
  39. 39.
    Miller AL (2005) Polypharmacy in schizophrenia: science, art, and fiction. Curr Psychosis Ther Rep 3(2):61–67CrossRefGoogle Scholar
  40. 40.
    Ranceva N, Ashraf W, Odelola D (2010) Antipsychotic polypharmacy in outpatients at Birch Hill Hospital: incidence and adherence to guidelines. J Clin Pharmacol 50(6):699–704PubMedCrossRefGoogle Scholar
  41. 41.
    Dussias P, Kalali AH, Citrome L (2010) Polypharmacy of schizophrenia. Psychiatry (Edgemont) 7(8):17–19Google Scholar
  42. 42.
    Chiu HF, Shum PS, Lam CW (1991) Psychotropic drug prescribing to chronic schizophrenics in a Hong Kong hospital 37(3):187–191. http://www.ncbi.nlm.nih.gov/pubmed/1743903
  43. 43.
    Sim K, Su A, Fujii S et al (2004) Antipsychotic polypharmacy in patients with schizophrenia: a multicentre comparative study in East Asia. Br J Clin Pharmacol 58(2):178–183PubMedCrossRefGoogle Scholar
  44. 44.
    Pi EH, Simpson GM (2005) Psychopharmacology: cross-cultural psychopharmacology: a current clinical perspective. Psychiatric Serv 56(1)Google Scholar
  45. 45.
    Kreyenbuhl JA, Valenstein M, McCarthy JF et al (2007) Long-term antipsychotic polypharmacy in the VA health system: patient characteristics and treatment patterns. Psychiatric Serv 58:489–495CrossRefGoogle Scholar
  46. 46.
    Verbenko NV (2007) Essays of ethnic psychiatry. In: Samokhvalov VP (ed) Simferopol, DoljaGoogle Scholar
  47. 47.
    Baandrup L, Allerup P, Nordentoft M et al (2010) Exploring regional variation in antipsychotic coprescribing practice: a Danish questionnaire survey. J Clin Psychiatry 71(11):1457–1464, Epub 2010 Oct 19PubMedCrossRefGoogle Scholar
  48. 48.
    Stahl SM (1999) Antipsychotic polypharmacy. Part 1: therapeutic option or dirty little secret? J Clin Psychiatry 60(7):425–426PubMedCrossRefGoogle Scholar
  49. 49.
    Miller AL, Craig CS (2002) Combination antipsychotics: pros, cons, and questions. Schizophr Bull 28(1):105–109PubMedCrossRefGoogle Scholar
  50. 50.
    Taylor D (2010) Antipsychotic polypharmacy – confusion reigns. Psychiatrist 34:41–43CrossRefGoogle Scholar
  51. 51.
    Rebala K, Mikulich A, Tsybovsky J et al (2007) Y-STR variation among Slavs: evidence for the Slavic homeland in the middle Dnieper basin. J Hum Genet 52(5):406–414PubMedCrossRefGoogle Scholar
  52. 52.
    Pickar D, Vinik J, Bartko JJ (2008) Pharmacotherapy of schizophrenic patients: preponderance of off-label drug use. PLoS One 3(9):e3150PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2013

Authors and Affiliations

  • Viktor P. Samokhvalov
    • 1
  • Oksana E. Samokhvalova
    • 2
  • Viktoria A. Verbenko
    • 3
  • Georgij N. Verbenko
    • 3
  1. 1.Deutsch-Russische Gesellschaft für Psychiatrie, Psychotherapie und Psychosoziale GesundheitNürnbergGermany
  2. 2.Department of PsychiatryCentral Military Hospital – Military University HospitalPragueCzech Republic
  3. 3.Department of PsychiatryCrimean Medical UniversitySimferopol, CrimeaUkraine

Personalised recommendations